Xinglong Jiang - Structure Therapeutics Senior Development
| GPCR Stock | 34.01 0.60 1.80% |
Executive
Xinglong Jiang is Senior Development of Structure Therapeutics American
| Address | 601 Gateway Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | (650) 457-1978 |
| Web | https://structuretx.com |
Structure Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1301) % which means that it has lost $0.1301 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1769) %, meaning that it created substantial loss on money invested by shareholders. Structure Therapeutics' management efficiency ratios could be used to measure how well Structure Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/26/2024, Return On Tangible Assets is likely to drop to -0.2. In addition to that, Return On Capital Employed is likely to drop to -0.24. At this time, Structure Therapeutics' Total Assets are relatively stable compared to the past year. As of 11/26/2024, Non Current Assets Total is likely to grow to about 8.8 M, while Non Currrent Assets Other are likely to drop slightly above 42.8 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| FACS FACS | Eledon Pharmaceuticals | N/A | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
| Camille MD | Amylyx Pharmaceuticals | 71 | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Gayle Gironda | Inozyme Pharma | N/A | |
| John Herberger | Eledon Pharmaceuticals | N/A | |
| Suba Krishnan | Mereo BioPharma Group | 59 | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Matthew Beck | Hookipa Pharma | N/A | |
| Pamela MPH | Disc Medicine | 56 | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Roman Necina | Hookipa Pharma | 56 | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| Michael Szumera | Hookipa Pharma | N/A | |
| Hua Yang | Disc Medicine | N/A | |
| Mark MBA | X4 Pharmaceuticals | 60 | |
| Thorsten Kirschberg | Biomea Fusion | 54 | |
| Srikanth Venkatraman | Disc Medicine | N/A | |
| Bryan JD | Eledon Pharmaceuticals | 44 | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.13 |
Structure Therapeutics Leadership Team
Elected by the shareholders, the Structure Therapeutics' board of directors comprises two types of representatives: Structure Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Structure. The board's role is to monitor Structure Therapeutics' management team and ensure that shareholders' interests are well served. Structure Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Structure Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jun Yoon, CFO Founder | ||
| Lani Ibarra, Senior Operations | ||
| Raymond Stevens, CEO Director | ||
| Hui Lei, Senior Chemistry | ||
| Xichen Lin, Chief Officer | ||
| Yingli Ma, Chief Officer | ||
| Fang Zhang, Executive Biology | ||
| Bob Gatmaitan, Senior People | ||
| Tony Peng, Senior Legal | ||
| Xinglong Jiang, Senior Development |
Structure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Structure Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 1 B | ||||
| Shares Outstanding | 57.26 M | ||||
| Shares Owned By Insiders | 4.84 % | ||||
| Shares Owned By Institutions | 95.16 % | ||||
| Number Of Shares Shorted | 10.44 M | ||||
| Price To Book | 2.13 X | ||||
| EBITDA | (102.46 M) | ||||
| Net Income | (89.62 M) |
Pair Trading with Structure Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Structure Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Structure Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Structure Stock
Moving against Structure Stock
| 0.47 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.45 | KEP | Korea Electric Power | PairCorr |
| 0.38 | RNXT | RenovoRx | PairCorr |
The ability to find closely correlated positions to Structure Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Structure Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Structure Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Structure Therapeutics American to buy it.
The correlation of Structure Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Structure Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Structure Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Structure Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.